Study summary

A HER2 bacterial vaccine was linked to higher 3-year survival after lung surgery

OST-HER2 trial · 41 people, phase 2b, interim · Reported September 2026

71.2%3-year survival, vs 45.8% in historical controls

What was tested

OST-HER2, a Listeria-based immunotherapy targeting HER2, after complete removal of lung metastases, compared with historical patients.

What they found

3-year survival was 71.2% vs 45.8% in historical controls.
No randomized comparison; some patients were lost to follow-up.

What it means

Promising but preliminary. A randomized trial would be needed.

Targeted Oncology ↗ ← Back to the outlook

Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.